GEMFIBROZIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Gemfibrozil, and what generic alternatives are available?
Gemfibrozil is a drug marketed by Natco, Purepac Pharm, Apotex, Ascent Pharms Inc, Aurobindo Pharma Ltd, Cadila, Cadila Pharms Ltd, Caribe Holdings, Chartwell Molecules, Chartwell Rx, Hikma Pharms, Impax Pharms, Invagen Pharms, Northstar Hlthcare, Norvium Bioscience, Sun Pharm Inds Inc, Teva, and Watson Labs. and is included in twenty NDAs.
The generic ingredient in GEMFIBROZIL is gemfibrozil. Thirty-four suppliers are listed for this compound. Additional details are available on the gemfibrozil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gemfibrozil
A generic version of GEMFIBROZIL was approved as gemfibrozil by CHARTWELL MOLECULES on September 27th, 1993.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GEMFIBROZIL?
- What are the global sales for GEMFIBROZIL?
- What is Average Wholesale Price for GEMFIBROZIL?
Summary for GEMFIBROZIL
| US Patents: | 0 |
| Applicants: | 18 |
| NDAs: | 20 |
| Finished Product Suppliers / Packagers: | 33 |
| Raw Ingredient (Bulk) Api Vendors: | 135 |
| Clinical Trials: | 43 |
| Patent Applications: | 4,007 |
| Drug Prices: | Drug price information for GEMFIBROZIL |
| Drug Sales Revenues: | Drug sales revenues for GEMFIBROZIL |
| What excipients (inactive ingredients) are in GEMFIBROZIL? | GEMFIBROZIL excipients list |
| DailyMed Link: | GEMFIBROZIL at DailyMed |
See drug prices for GEMFIBROZIL
Recent Clinical Trials for GEMFIBROZIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| St. Louis University | Early Phase 1 |
| Polaryx Therapeutics, Inc. | Phase 3 |
| Bristol-Myers Squibb | Phase 1 |
Pharmacology for GEMFIBROZIL
| Drug Class | Peroxisome Proliferator Receptor alpha Agonist |
| Mechanism of Action | Peroxisome Proliferator-activated Receptor alpha Agonists |
Medical Subject Heading (MeSH) Categories for GEMFIBROZIL
Anatomical Therapeutic Chemical (ATC) Classes for GEMFIBROZIL
US Patents and Regulatory Information for GEMFIBROZIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Natco | GEMFIBROZIL | gemfibrozil | CAPSULE;ORAL | 073466-001 | Jan 25, 1993 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva | GEMFIBROZIL | gemfibrozil | TABLET;ORAL | 074256-001 | Oct 31, 1993 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cadila Pharms Ltd | GEMFIBROZIL | gemfibrozil | TABLET;ORAL | 203266-001 | Jun 17, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ascent Pharms Inc | GEMFIBROZIL | gemfibrozil | TABLET;ORAL | 214603-001 | Jan 13, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Impax Pharms | GEMFIBROZIL | gemfibrozil | TABLET;ORAL | 078207-001 | Jun 1, 2007 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
